Related by context. Frequent words. (Click for all words.) 75 Pivotal Phase III 74 Well Tolerated 73 Pivotal Phase 72 Chronic Hepatitis C 72 Clinical Trial Results 72 Preclinical Data 72 Drug Candidate 72 Initiate Phase 71 Phase III Clinical Trial 71 II Clinical Trial 71 Presents Positive 71 Single Dose 70 Patient Enrollment 70 Monotherapy 70 Completes Enrollment 70 Renal Cell Carcinoma 70 Recombinant Human 70 Initiates Phase II 70 Generic Version 70 Advanced Prostate Cancer 70 Benign Prostatic Hyperplasia 69 Metastatic Melanoma 69 Cholesterol Drug 69 Initiates Phase 69 Commences Phase 69 Blood Thinner 69 Patients Undergoing 68 Patients Treated 68 Chronic Hepatitis B 68 Tumor Growth 68 Elderly Patients 68 Phase III Trial 68 FDA Clears 68 Postmenopausal Women 68 Prostate Cancer Patients 68 Low Dose 68 Pediatric Patients 68 Antifungal 67 Lung Cancer Patients 67 Develop Novel 67 J Am Coll 67 Chronic Lymphocytic Leukemia 67 Prostate Cancer Treatment 67 Stomach Cancer 67 Drug Resistant 67 Pivotal Trial 66 Pivotal Study 66 Diabetic Patients 66 Blood Clots 66 Significantly Improves 66 Gastric Cancer 66 Cancer Cells 66 Epratuzumab 66 Heart Failure Patients 66 Significantly Reduces 65 Study Demonstrates 65 FDA Accepts 65 Inhibits 65 Hepatitis C Virus 65 Increases Risk 65 Gene Mutation 65 Pulmonary Arterial Hypertension 65 Combination Therapy 65 Shows Promise 65 Venous Thromboembolism 65 Reduces Risk 65 Golimumab 65 Overactive Bladder 65 Metastatic Colorectal Cancer 65 Breast Cancer Treatment 65 Induces 64 Coadministration 64 Meta Analysis 64 Antipsychotic 64 Tolerability 64 Monoclonal Antibodies 64 Breast Cancer Patients 64 Dasatinib 64 Generalized Anxiety Disorder 64 Cervical Cancer Vaccine 64 Capecitabine 64 Announces FDA Clearance 64 Cardiovascular Events 64 Monoclonal Antibody 64 Receives FDA Clearance 63 Blood Vessels 63 Increased Risk 63 Am J Clin 63 Newly Diagnosed 63 Gum Disease 63 Gemcitabine 63 J Am Acad 63 Long Lasting 63 Pediatr 63 Bortezomib 63 Anti Inflammatory 63 Tacrolimus 63 Obstet Gynecol 63 Cancer Treatments 63 Am J Respir 63 RNAi Therapeutics